Chin. J. Org. Chem. ›› 2019, Vol. 39 ›› Issue (4): 974-981.DOI: 10.6023/cjoc201808018 Previous Articles     Next Articles



高梦远a, 刘洪涛b, 连玉菲b, 高欣丰a, 耿云鹤a, 李文燕a   

  1. a 河北师范大学化学与材料科学学院 石家庄 050024;
    b 河北省人民医院药学部 石家庄 050051
  • 收稿日期:2018-08-16 修回日期:2018-10-15 发布日期:2018-11-30
  • 通讯作者: 李文燕
  • 基金资助:


Research Progress in Prodrugs of Acyclic Nucleoside Phosphonates Antiviral Agents

Gao Mengyuanaa, Liu Hongtaobb, Lian Yufeibb, Gao Xinfengaa, Geng Yunheaa, Li Wenyana   

  1. a Hebei Normal University, College of Chemistry & Material Science, Shijiazhuang 050024;
    b Department of Pharmacy, Hebei General Hospital, Shijiazhuang 050051
  • Received:2018-08-16 Revised:2018-10-15 Published:2018-11-30
  • Contact: 10.6023/cjoc201808018
  • Supported by:

    Project supported by the Natural Science Foundation of Hebei Province (No.H2018307055) and the Technology Innovation Foundation of Hebei Normal University (No.L2017K06).

More and more attention has been focused on acyclic nucleoside phosphonates (ANPs) antiviral agents which were wildly used in clinical therapy. However, poor oral bioavailability and high toxicity directly related to the phosphonate charge were serious and unnegligible especially for the treatment of chronic diseases such as hepatitis B virus (HBV) and human immunodeficiency virus (HIV). Preparing appropriate forms of prodrug could enhance the oral bioavailability and reduce the toxicity because of the smooth absorption of prodrugs and the release of active drug only at the target. This review summarizes some recent progress in prodrugs of ANPs antiviral agents based on the structures of tenofovir, adefovir and cidofovir.

Key words: acyclic nucleoside phosphonates (ANPs), antiviral agents, prodrug